Intellia Therapeutics, Inc. Forecast, price target & analysts
Intellia Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Intellia Therapeutics, Inc. Classifications & Recommendation:
Intellia Therapeutics, Inc. Price Target
| Target Price | $47.05 |
| Price | $10.86 |
| Potential |
333.22%
register free of charge
|
| Number of Estimates | 21 |
|
21 Analysts have issued a price target Intellia Therapeutics, Inc. 2026 .
The average Intellia Therapeutics, Inc. target price is $47.05.
This is
333.22%
register free of charge
$106.00
876.06%
register free of charge
$10.00
7.92%
register free of charge
|
|
| A rating was issued by 24 analysts: 18 Analysts recommend Intellia Therapeutics, Inc. to buy, 6 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Intellia Therapeutics, Inc. stock has an average upside potential 2026 of
333.22%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2029
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 36.28 | 53.93 |
| 30.39% | 48.65% | |
| EBITDA Margin | -1,395.59% | -955.13% |
| 61.43% | 31.56% | |
| Net Margin | -1,520.83% | -1,002.72% |
| 26.40% | 34.07% |
24 Analysts have issued a sales forecast Intellia Therapeutics, Inc. 2024 . The average Intellia Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Intellia Therapeutics, Inc. EBITDA forecast 2024. The average Intellia Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
25 Intellia Therapeutics, Inc. Analysts have issued a net profit forecast 2024. The average Intellia Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2029
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -5.42 | -5.31 |
| 12.01% | 2.03% | |
| P/E | negative | |
| EV/Sales | 10.08 |
25 Analysts have issued a Intellia Therapeutics, Inc. forecast for earnings per share. The average Intellia Therapeutics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Intellia Therapeutics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Intellia Therapeutics, Inc....
Current Intellia Therapeutics, Inc. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Morgan Stanley | Locked ➜ Locked | Locked | Jan 27 2025 |
| Goldman Sachs | Locked ➜ Locked | Locked | Jan 14 2025 |
| Oppenheimer | Locked ➜ Locked | Locked | Jan 13 2025 |
| Wells Fargo | Locked ➜ Locked | Locked | Jan 10 2025 |
| BMO Capital | Locked ➜ Locked | Locked | Jan 10 2025 |
| Canaccord Genuity | Locked ➜ Locked | Locked | Nov 19 2024 |
| Wedbush | Locked ➜ Locked | Locked | Nov 18 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Morgan Stanley: Locked ➜ Locked
|
Jan 27 2025 |
|
Locked
Goldman Sachs: Locked ➜ Locked
|
Jan 14 2025 |
|
Locked
Oppenheimer: Locked ➜ Locked
|
Jan 13 2025 |
|
Locked
Wells Fargo: Locked ➜ Locked
|
Jan 10 2025 |
|
Locked
BMO Capital: Locked ➜ Locked
|
Jan 10 2025 |
|
Locked
Canaccord Genuity: Locked ➜ Locked
|
Nov 19 2024 |
|
Locked
Wedbush: Locked ➜ Locked
|
Nov 18 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
